X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40) 40
humans (37) 37
oncology (32) 32
female (30) 30
male (27) 27
adult (23) 23
aged (21) 21
middle aged (21) 21
cancer (15) 15
chemotherapy (13) 13
patients (13) 13
abridged index medicus (12) 12
care and treatment (11) 11
child, preschool (11) 11
research (11) 11
article (10) 10
child (10) 10
pediatrics (10) 10
treatment outcome (10) 10
tumors (10) 10
dosage and administration (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
carcinoma (8) 8
drug administration schedule (8) 8
toxicity (8) 8
abstracts (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
children (7) 7
clinical neurology (7) 7
disease-free survival (7) 7
head and neck neoplasms - drug therapy (7) 7
magnetic resonance imaging (7) 7
metastasis (7) 7
adolescent (6) 6
analysis (6) 6
brain tumors (6) 6
cancer therapies (6) 6
clinical trials (6) 6
drug therapy (6) 6
health aspects (6) 6
medicine & public health (6) 6
mutation (6) 6
radiotherapy (6) 6
sirolimus - administration & dosage (6) 6
sirolimus - analogs & derivatives (6) 6
squamous cell carcinoma (6) 6
therapy (6) 6
aged, 80 and over (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
carcinoma, squamous cell - drug therapy (5) 5
cisplatin (5) 5
dose-response relationship, drug (5) 5
maximum tolerated dose (5) 5
medical research (5) 5
metastases (5) 5
neoplasm metastasis (5) 5
neoplasm recurrence, local - drug therapy (5) 5
neoplasm staging (5) 5
retrospective studies (5) 5
sirolimus - adverse effects (5) 5
trial (5) 5
young adult (5) 5
antineoplastic agents - adverse effects (4) 4
bevacizumab (4) 4
brain (4) 4
brain cancer (4) 4
cisplatin - administration & dosage (4) 4
everolimus (4) 4
expression (4) 4
fatigue (4) 4
glioma (4) 4
head and neck cancer (4) 4
head and neck neoplasms - pathology (4) 4
hyperglycemia (4) 4
infant (4) 4
medicine, general & internal (4) 4
mortality (4) 4
mtor (4) 4
paclitaxel (4) 4
patient outcomes (4) 4
personality (4) 4
psychology, social (4) 4
radiology, nuclear medicine & medical imaging (4) 4
rapamycin (4) 4
solid tumors (4) 4
sorafenib (4) 4
squamous (4) 4
stroke (4) 4
studies (4) 4
surgery (4) 4
thyroid cancer (4) 4
usage (4) 4
activation (3) 3
administration, oral (3) 3
anemia (3) 3
anticoagulants (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast cancer (3) 3
cells (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 7, pp. 623 - 632
Inhibition of mitogen-activated protein kinase resulted in an increase in expression of the sodium–iodide symporter in 12 of 20 patients, 8 of whom had... 
CELLS | MEDICINE, GENERAL & INTERNAL | ACTIVATION | THERAPY | BRAF MUTATIONS | PHASE-II | PAPILLARY | DIFFERENTIATION | RADIOACTIVE IODINE | CARCINOMA | EXPRESSION | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Positron-Emission Tomography | Multimodal Imaging | Iodine Radioisotopes - therapeutic use | Neoplasm Metastasis | Thyrotropin Alfa - pharmacology | Adult | Female | Radiometry | Benzimidazoles - therapeutic use | MAP Kinase Kinase 1 - antagonists & inhibitors | Thyroid Neoplasms - radiotherapy | Iodine Radioisotopes - pharmacokinetics | Symporters - metabolism | Thyroid Neoplasms - genetics | MAP Kinase Kinase 2 - antagonists & inhibitors | Benzimidazoles - pharmacology | Aged | Symporters - drug effects | Mutation | Mitogen-Activated Protein Kinases - metabolism | Thyroid Neoplasms - pathology | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Thyroid cancer | Product/Service Evaluations | Dosage and administration | Drug therapy | Isotopes | Methods | Cancer | Iodine | Animal models | MAP kinase | Antagonists | Thyroid gland | Kinases | Cancer therapies | Patients | Myelodysplastic syndrome | Metastases | Thyroid-stimulating hormone | Sodium | Thyroglobulin | Protein kinase | Dosimetry | Positron emission tomography | Thyroid | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Neuro-Oncology, ISSN 1522-8517, 04/2019, Volume 21, Issue Supplement_2, pp. ii95 - ii95
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2018, Volume 20, Issue suppl_6, pp. vi185 - vi185
Abstract BACKGROUND Cerebral cavernomas are encountered in pediatric patients with central nervous system (CNS) tumors and may cause neurological compromise.... 
Journal Article
Neuro-Oncology, ISSN 1522-8517, 06/2018, Volume 20, Issue suppl_2, pp. i175 - i175
Abstract BACKGROUND Cerebral cavernomas are incidental findings in pediatric patients with primary or metastatic central nervous system (CNS) tumors. Lesional... 
Abstracts
Journal Article
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4114 - 4121
Sorafenib and temsirolimus appear to be an active combination in patients with radioactive‐iodine refractory thyroid cancer, even in those who previously... 
mutation | v‐Raf murine sarcoma viral oncogene homolog B | sorafenib | anaplastic thyroid cancer | BRAF | thyroid cancer | mammalian target of rapamycin (mTOR) inhibition | v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation | BROAD-SPECTRUM | II TRIAL | MTOR | LENVATINIB | ONCOLOGY | HISTOLOGIC SUBTYPES | DOUBLE-BLIND | TARGETS | CARCINOMA | PROGRESSION | Niacinamide - analogs & derivatives | Adenocarcinoma, Follicular - radiotherapy | Adenocarcinoma, Follicular - pathology | Humans | Middle Aged | Radiation Tolerance | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Adenocarcinoma, Follicular - genetics | Male | Antineoplastic Agents - therapeutic use | Iodine Radioisotopes - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adenocarcinoma, Follicular - drug therapy | Aged, 80 and over | Adult | Female | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Drug Administration Schedule | Niacinamide - adverse effects | Treatment Outcome | Thyroid Neoplasms - radiotherapy | Niacinamide - administration & dosage | Disease-Free Survival | Sirolimus - administration & dosage | Thyroid Neoplasms - genetics | Phenylurea Compounds - administration & dosage | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Thyroid Neoplasms - pathology | Temsirolimus | Cancer patients | Care and treatment | Dosage and administration | Thyroid cancer | Drug therapy | TOR protein | Intravenous administration | Mucositis | Toxicity | Anemia | Cytotoxicity | Fatigue | Rapamycin | Metastasis | Cancer therapies | Patients | Metastases | Thyroid carcinoma | Hyperglycemia | Chemotherapy | Inhibitors | Quality | Response rates | Background radiation | Iodine | Cancer | Thyroid | Index Medicus | Abridged Index Medicus
Journal Article
Breast Cancer Research, ISSN 1465-5411, 08/2017, Volume 19, Issue 1, pp. 89 - 89
Journal Article
Clinical Nuclear Medicine, ISSN 0363-9762, 01/2018, Volume 43, Issue 1, pp. 19 - 22
Journal Article
Neuro-Oncology, ISSN 1522-8517, 11/2018, Volume 20, Issue suppl_6, pp. vi236 - vi237
Abstract BACKGROUND The incidence of large congenital melanocytic nevi (LCMN) is 1/20,000 with 25% of children diagnosed with neurocutaneous melanocytosis... 
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 87, Issue 3, pp. 479 - 486
Purpose Elevated expression of eukaryotic protein synthesis initiation factor 4E (eIF4E) in histologically cancer-free margins of resected head and neck... 
Radiology | Hematology, Oncology and Palliative Medicine | Chemoradiotherapy - adverse effects | Injections, Intravenous | Prospective Studies | TOR Serine-Threonine Kinases - metabolism | Carcinoma, Squamous Cell - metabolism | Humans | Middle Aged | Eukaryotic Initiation Factor-4E - metabolism | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - administration & dosage | Neoplasm Proteins - metabolism | Head and Neck Neoplasms - metabolism | Cisplatin - administration & dosage | TOR Serine-Threonine Kinases - antagonists & inhibitors | Squamous Cell Carcinoma of Head and Neck | Radiation-Sensitizing Agents - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Everolimus | Sirolimus - adverse effects | Radiotherapy Dosage | Chemoradiotherapy - methods | Sirolimus - analogs & derivatives | Drug Administration Schedule | Administration, Oral | Radiotherapy, Intensity-Modulated - methods | Head and Neck Neoplasms - therapy | Carcinoma, Squamous Cell - therapy | Radiation-Sensitizing Agents - adverse effects | Sirolimus - administration & dosage | Maximum Tolerated Dose | Cisplatin - adverse effects | Aged | Sects | Squamous cell carcinoma | Nuclear radiation | Protein biosynthesis | Angiogenesis inhibitors | Radiotherapy | Cisplatin | Index Medicus | PHARYNX | HEAD | DOSES | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE | TOXICITY | NECK | RADIOTHERAPY | COMBINED THERAPY | PLATINUM COMPLEXES
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 07/2017, Volume 64, Issue 7, p. n/a
BackgroundThe PI3K/AKT/mTOR pathway is aberrantly activated in many pediatric solid tumors including gliomas and medulloblastomas. Preclinical data in a... 
mTOR | AKT | temsirolimus | phase I clinical trials | perifosine | GLIOMAS | ACTIVATION | NEUROBLASTOMA | CANCER | TRIAL | INHIBITION | ONCOLOGY | PATHWAY | RHABDOMYOSARCOMA | PEDIATRICS | HEMATOLOGY | MEDULLOBLASTOMA | Sirolimus - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Male | Sirolimus - pharmacokinetics | Phosphorylcholine - analogs & derivatives | Phosphorylcholine - administration & dosage | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Young Adult | Sirolimus - administration & dosage | Maximum Tolerated Dose | Phosphorylcholine - pharmacokinetics | Adolescent | Phosphorylcholine - adverse effects | Female | Child | Sirolimus - adverse effects | Pediatrics | Relapse | Oncology, Experimental | Brain tumors | Clinical trials | Research | Antineoplastic agents | Diseases | Antimitotic agents | Hypercholesterolemia | Gliomas | Analysis | Cancer | TOR protein | Slopes | Brain | Toxicity | Brain cancer | Rhabdomyosarcoma | AKT protein | Neuroblastoma | Inhibition | Age | Neutropenia | Thrombocytopenia | Pharmacology | Patients | Constraining | 1-Phosphatidylinositol 3-kinase | Inhibitors | Glioma | Lymphopenia | Medulloblastoma | Adults | Feasibility | Solid tumors | Aberration | Pharmacokinetics | Tumors | Index Medicus
Journal Article
Developmental Medicine & Child Neurology, ISSN 0012-1622, 06/2012, Volume 54, Issue 6, pp. 563 - 568
Journal Article